Stimulus-responsive self-assembled prodrugs in cancer therapy

Dong, Xiao; Brahma, Rajeev K.; Fang, Chao; Yao, Shao Q.

doi:10.1039/d2sc01003h

Cited by 73 publications

(49 citation statements)

References 156 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As more and more stimuli-responsive variable chemical structures are developed, prodrugs can now simultaneously respond to multiple activation signals. Due to the complexity of the tumor microenvironment, the introduction of a multistimuli-responsive activation mechanism has become an important research direction. , Multistimuli responsiveness can generally be categorized as “and” and “or” logic gates based on different design logics. Traditional stimuli-responsive materials could only recognize simple single input.…”

Section: Discussionmentioning

confidence: 99%

Emerging Strategies in Stimuli-Responsive Prodrug Nanosystems for Cancer Therapy

Ding

Chen²,

Zeng

et al. 2022

ACS Nano

View full text Add to dashboard Cite

Prodrugs are chemically modified drug molecules that are inactive before administration. After administration, they are converted in situ to parent drugs and induce the mechanism of action. The development of prodrugs has upgraded conventional drug treatments in terms of bioavailability, targeting, and reduced side effects. Especially in cancer therapy, the application of prodrugs has achieved substantial therapeutic effects. From serendipitous discovery in the early stage to functional design with pertinence nowadays, the importance of prodrugs in drug design is self-evident. At present, studying stimuli-responsive activation mechanisms, regulating the stimuli intensity in vivo, and designing nanoscale prodrug formulations are the major strategies to promote the development of prodrugs. In this review, we provide an outlook of recent cutting-edge studies on stimuli-responsive prodrug nanosystems from these three aspects. We also discuss prospects and challenges in the future development of such prodrugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Emerging Strategies in Stimuli-Responsive Prodrug Nanosystems for Cancer Therapy

Ding

Chen²,

Zeng

et al. 2022

ACS Nano

View full text Add to dashboard Cite

show abstract

“…Cancer cells overexpressing enzymes can facilitate the controllable release of drugs, amplifying the therapeutic effect of drugs [ 62 ]. Kim et al have developed visible-light-induced apoptosis activatable nanoparticles of the photosensitizer (Ce6)-caspase-3 cleavable peptide (Asp-Glu-Val-Asp, DEVD)-anticancer drug monomethyl auristatin E (MMAE) conjugate [ 63 ].…”

Section: Peptide-based Assembly For Theranostic Applicationsmentioning

confidence: 99%

Self-Assembly of Small Organic Molecules into Luminophores for Cancer Theranostic Applications

Wang

Yang

et al. 2022

Biosensors

View full text Add to dashboard Cite

Self-assembled biomaterials have been widely explored for real-time fluorescence imaging, imaging-guided surgery, and targeted therapy for tumors, etc. In particular, small molecule-based self-assembly has been established as a reliable strategy for cancer theranostics due to the merits of small-sized molecules, multiple functions, and ease of synthesis and modification. In this review, we first briefly introduce the supramolecular chemistry of small organic molecules in cancer theranostics. Then, we summarize and discuss advanced small molecule-based self-assembly for cancer theranostics based on three types, including peptides, amphiphilic molecules, and aggregation-induced emission luminogens. Finally, we conclude with a perspective on future developments of small molecule-based self-assembled biomaterials integrating diagnosis and therapy for biomedical applications. These applications highlight the opportunities arising from the rational design of small organic molecules with self-assembly properties for precision medicine.

show abstract

“…Nano-delivery systems have been widely used for improving the utilization of drugs. [6][7][8][9][10][11][12][13][14] The use of nanocarriers to improve the BBB-penetration efficiency of drugs has been extensively studied. [15][16][17][18][19] However, there are few reported nanocarriers for delivering AEDs, and most of them are single-targeted nanocarriers, which still cause side effects.…”

Section: Introductionmentioning

confidence: 99%

Dual targeting nanoparticles for epilepsy therapy

Hou

Wang²,

Xiao

et al. 2022

Chem. Sci.

View full text Add to dashboard Cite

show abstract

Stimulus-responsive self-assembled prodrugs in cancer therapy

Abstract: Small-molecule prodrug have become the main toolbox to improve unfavorable physicochemical properties of potential therapeutic compounds in contemporary anti-cancer drug development. Many approved small-molecule prodrugs, however, still face key challenges...

Cited by 73 publications

References 156 publications

Emerging Strategies in Stimuli-Responsive Prodrug Nanosystems for Cancer Therapy

Emerging Strategies in Stimuli-Responsive Prodrug Nanosystems for Cancer Therapy

Self-Assembly of Small Organic Molecules into Luminophores for Cancer Theranostic Applications

Dual targeting nanoparticles for epilepsy therapy

Contact Info

Product

Resources

About